Functional Dyspepsia: Rome IV Subtypes, H. pylori Testing, and Step-Up Therapy

Functional Dyspepsia: Rome IV Subtypes, H. pylori Testing, and Step-Up Therapy

A practical guideline for evaluating dyspepsia, applying age-based test-and-treat or endoscopy-first strategies, and managing PDS and EPS subtypes with PPIs, prokinetics, and gut-brain neuromodulators.

Executive Summary

Functional dyspepsia (FD) is a common disorder of gut-brain interaction affecting 10-20% of adults, defined by Rome IV criteria as bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning without structural explanation. Two subtypes guide therapy: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Initial management depends on age and alarm features—patients under 60 without alarms undergo H. pylori test-and-treat in higher-prevalence regions, while those 60+ require upfront endoscopy. Pharmacotherapy progresses from PPIs (particularly EPS) and prokinetics (particularly PDS) to neuromodulators (tricyclic antidepressants, mirtazapine) and gut-brain behavioral therapy in refractory disease.

10-20%Adult prevalence
PDS / EPSRome IV subtypes
8-10PPI NNT (EPS)
≥60 yrUpfront endoscopy

S1. Pathophysiology and Subtype Definitions

Disorder of Gut-Brain Interaction

Functional dyspepsia, like irritable bowel syndrome, is reframed under Rome IV as a disorder of gut-brain interaction with measurable peripheral and central abnormalities. Pathophysiologic contributors include impaired gastric accommodation (failure of fundus relaxation following a meal, found in 30-40% of patients), delayed gastric emptying (in 20-30%, particularly PDS), visceral hypersensitivity to gastric distension (in 30-40%), duodenal eosinophilia and low-grade inflammation, increased intestinal permeability, gastric and duodenal microbiota changes, and central pain processing alterations. Genetic factors, prior gastroenteritis (post-infectious FD parallels post-infectious IBS), psychological stress, and early life adversity modulate susceptibility.

Postprandial Distress Syndrome (PDS)

PDS is characterized by symptoms induced or worsened by meals: bothersome postprandial fullness (heavy or full feeling after a normal-sized meal) or bothersome early satiation (inability to finish a normal-sized meal). Pathophysiology emphasizes impaired accommodation and delayed gastric emptying. Patients often describe a relationship between symptoms and meal volume or composition. Distinguishing PDS from gastroparesis requires gastric emptying scintigraphy when objective evaluation is needed; many patients have mild emptying abnormalities that fall below the gastroparesis threshold.

Epigastric Pain Syndrome (EPS)

EPS is characterized by bothersome epigastric pain or epigastric burning that is intermittent (at least once weekly), localized to the epigastrium, not generalized or occurring in other abdominal/chest regions, and not relieved by defecation or passage of flatus (which would suggest IBS). Pain may or may not be related to meals. Pathophysiology emphasizes visceral hypersensitivity, mucosal inflammation (duodenal eosinophilia), and central pain processing. EPS responds preferentially to PPIs and neuromodulators.

Subtype Overlap and Variability

Approximately 30-40% of patients meet criteria for both PDS and EPS simultaneously (overlap subtype). Subtype assignments may shift over time. Co-existence with gastroesophageal reflux disease, irritable bowel syndrome, and chronic nausea is common; multiple Rome IV diagnoses may apply concurrently. The therapeutic implication is that combination therapy (e.g., PPI plus prokinetic, PPI plus neuromodulator) is often necessary in patients with overlapping symptoms or partial response to single-agent therapy.

Functional Dyspepsia Pathophysiology Schematic showing peripheral and central mechanisms in functional dyspepsia: impaired accommodation, delayed emptying, visceral hypersensitivity, duodenal inflammation, brain-gut axis Functional Dyspepsia: Disorder of Gut-Brain Interaction Impaired Accommodation Failure of fundus to relax post-meal (30-40%) Delayed Emptying Mild gastric stasis (20-30%, esp PDS) Visceral Hypersensitivity Lower distension threshold (30-40%, esp EPS) Duodenal Inflammation Eosinophilia, mast cells Permeability changes PDS Subtype Postprandial fullness, early satiation Therapy: prokinetics, accommodation agents EPS Subtype Epigastric pain or burning Therapy: PPI, neuromodulators
Pathophysiologic mechanisms of functional dyspepsia and their relationship to PDS and EPS subtypes.
Clinical PearlPost-infectious functional dyspepsia parallels post-infectious IBS in mechanism. About 5-10% of patients develop persistent FD-type symptoms after acute gastroenteritis, particularly Salmonella and norovirus. Recognizing this onset pattern reframes the patient narrative, supports the legitimacy of symptoms, and guides expectations: post-infectious FD often resolves over months to years but may benefit from early gut-directed therapies. Asking explicitly about gastroenteritis preceding symptom onset is a high-yield history element.
Common PitfallIndefinite PPI escalation without re-evaluation. Patients with refractory dyspepsia on high-dose PPI for years often have predominantly PDS (postprandial distress) where PPI provides minimal benefit. Reassess subtype, consider prokinetic addition, and trial neuromodulator (low-dose TCA or mirtazapine). Periodic PPI taper attempts are reasonable; many patients can step down to maintenance H2RA or as-needed dosing without symptom escalation.

S2. Rome IV Criteria and Differential Diagnosis

Rome IV Criteria for Functional Dyspepsia

Rome IV Diagnostic Criteria One or more of: bothersome postprandial fullness, bothersome early satiation, bothersome epigastric pain, or bothersome epigastric burning, AND no evidence of structural disease (including upper endoscopy when indicated) likely to explain symptoms. Symptoms must be present at least 3 days per week for the last 3 months with onset at least 6 months before diagnosis. Subtypes: PDS (postprandial fullness or early satiation, ≥3 days/week, severe enough to impact usual activities), EPS (epigastric pain or burning, ≥1 day/week, intermittent, localized to epigastrium, not relieved by defecation, no biliary/pancreatic features). Both subtypes can coexist (overlap).

Differential Diagnosis

ConditionDiscriminating FeaturesWorkup
Peptic ulcer diseaseBurning epigastric pain, nocturnal symptoms, NSAID/H. pyloriUpper endoscopy with biopsy
GERD with overlapHeartburn, regurgitation as predominant symptomsSymptom-based; PPI trial; pH monitoring if refractory
Gastric / esophageal cancerAge >60, weight loss, dysphagia, anemia, family historyUpper endoscopy with biopsy
GastroparesisPostprandial fullness, nausea, vomiting; diabetes, post-surgical, idiopathic4-hour gastric emptying scintigraphy >10% retention
Biliary colic / chronic cholecystitisRight upper quadrant pain, post-fatty meal, radiation to back/scapulaRight upper quadrant ultrasound; HIDA if normal US
Chronic pancreatitisEpigastric pain radiating to back, weight loss, steatorrhea, alcohol/geneticCT or MRCP; fecal elastase <200; secretin MRCP
Pancreatic cancerPainless jaundice or epigastric pain to back, weight loss, new diabetesCT pancreas protocol; CA 19-9; EUS with FNA if mass
Mesenteric ischemia (chronic)Postprandial pain, weight loss, food fear, atherosclerotic risk factorsCT or MR angiography of mesenteric arteries
Celiac disease (atypical)Bloating, diarrhea, anemia, family historytTG-IgA + total IgA; duodenal biopsy
Eosinophilic gastritisPersistent symptoms, peripheral eosinophilia, atopyUpper endoscopy with biopsy (eosinophil count)
Medication-inducedNSAIDs, bisphosphonates, iron, potassium, antibioticsMedication review and trial of cessation
Cardiac (atypical angina)Exertional symptoms, radiation to arm/jaw, cardiovascular riskECG, troponin, stress testing if appropriate
Functional Dyspepsia — Comparison Comparison table: Functional Dyspepsia — Comparison PDS EPS PDS + EPS Description Postprandial distress: bothersome fullness OR early satiety several × week Epigastric pain syndrome: bothersome epigastric pain or burning ≥1×/wk Mixed symptoms; common in clinical practice
Functional Dyspepsia — Comparison

S3. Diagnostic Workup, Endoscopy, and H. pylori Testing

Initial Evaluation

History should establish symptom predominance (PDS vs EPS), duration, alarm features, GERD-like features (heartburn, regurgitation), bowel habit (IBS overlap), prior infections, medications (NSAIDs, bisphosphonates, iron, K, calcium channel blockers), and psychosocial factors. Examine for epigastric tenderness, palpable mass, lymphadenopathy (Virchow node, Sister Mary Joseph), jaundice, and signs of weight loss. Initial laboratories include CBC (anemia, eosinophilia), CMP (renal/hepatic function), TSH (hyper/hypothyroidism), and celiac serology (tTG-IgA + total IgA) in high-prevalence populations or with diarrhea/bloating overlap.

Age-Based Endoscopy Strategy

ACG / CAG 2017 Recommendations Patients ≥60 years: upfront upper endoscopy to exclude upper GI malignancy (incidence rises sharply after age 60; gastric cancer prevalence exceeds 1% in many populations). Patients <60: H. pylori test-and-treat is first-line in regions with H. pylori prevalence >10% (most of the world); empiric PPI trial when prevalence is low. Upper endoscopy regardless of age when alarm features are present: unintentional weight loss >5%, dysphagia or odynophagia, persistent vomiting, GI bleeding (overt or iron deficiency anemia), palpable abdominal mass or lymphadenopathy, family history of upper GI cancer in first-degree relative, or persistent severe symptoms despite empiric therapy.

H. pylori Testing

TestSensitivitySpecificityNotes
Urea breath test (13C or 14C)95-100%95-100%Gold standard for active infection; hold PPI 2 weeks, antibiotics/bismuth 4 weeks
Stool antigen test94%97%Equivalent to UBT; same hold periods; preferred for confirmation of eradication
Endoscopic biopsy (RUT)85-95%95-100%Use during scheduled endoscopy; reduced sensitivity with PPI/recent bleeding; sample antrum + corpus
Endoscopic biopsy (histology)95%95-100%Use during scheduled endoscopy; can identify atrophy, intestinal metaplasia, dysplasia
Serology (IgG)85%79%NOT recommended for active infection or eradication confirmation; cannot distinguish active from past

H. pylori Eradication Regimens

First-line therapy depends on local clarithromycin resistance pattern. Where clarithromycin resistance is <15%, standard triple therapy may be acceptable; in most regions resistance now exceeds 15%, mandating bismuth quadruple or vonoprazan-based therapy as first-line. Confirm eradication 4 weeks after completion using stool antigen or urea breath test (off PPI 2 weeks).

RegimenComponentsDurationEradication
Bismuth quadruple (preferred first-line)PPI BID + bismuth subsalicylate 525 mg QID + metronidazole 500 mg TID + tetracycline 500 mg QID10-14 days85-93%
Vonoprazan triple (where available)Vonoprazan 20 mg BID + amoxicillin 1000 mg BID + clarithromycin 500 mg BID14 days87-90%
Vonoprazan dual (penicillin-tolerant)Vonoprazan 20 mg BID + amoxicillin 1000 mg TID14 days80-84%
Standard triple (only if clarithro resist <15%)PPI BID + clarithromycin 500 mg BID + amoxicillin 1000 mg BID14 days70-85%
Levofloxacin rescue (after 1 failure)PPI BID + levofloxacin 500 mg daily + amoxicillin 1000 mg BID14 days70-80%
Rifabutin rescue (after 2 failures)PPI BID + rifabutin 150 mg BID + amoxicillin 1000 mg BID10-12 days70-75%

Stepwise management

Functional dyspepsia: step-up treatment

For adults with FD after workup, including upper endoscopy when indicated.

  1. 1. Start: medication review and H. pylori test-and-treat

    • Stop NSAIDs and other aggravating drugs when possible
    • Urea breath test, stool antigen, or biopsy at endoscopy; not serology
    • Hold PPI 2 weeks and antibiotics or bismuth 4 weeks before each test; retest ≥4 weeks after treatment
  2. 2. H. pylori negative, or eradicated but still symptomatic: PPI

    • Standard dose once daily for 4‑8 weeks, e.g., omeprazole 20 mg
    • Lowest effective dose; higher doses add no benefit
  3. 3. No response to PPI by 8‑12 weeks: neuromodulator

    • Low-dose amitriptyline or nortriptyline at bedtime
    • Mirtazapine at bedtime, especially with early satiation and weight loss
    • Itopride or acotiamide add-on where available

    Caution: Check each drug’s label for contraindications and interactions before starting; doses are in the article.

  4. 4. Refractory FD: add CBT or gut‑directed hypnotherapy

    • Screen for anxiety, depression and eating disorders; refer to psychiatry or psychology if they significantly impair function or response
  5. 5. Still refractory: recheck before escalating

    • Look for a missed diagnosis (e.g., duodenal biopsy)
    • Confirm H. pylori eradication status; refer to a GI specialist
Move up a step only when symptoms persist. Sources: This article, S3–S7 and FAQ; ACG/CAG 2017; ACG H. pylori 2024; BSG 2022; Maastricht VI 2022; FDA drug labels

S4. First-Line Pharmacotherapy

Lifestyle and Dietary Modifications

Initial measures include smaller more frequent meals, slow eating with thorough chewing, avoidance of dietary triggers identified by patient (commonly fatty foods, spicy foods, caffeine, alcohol, carbonated beverages), weight loss in overweight patients (improves symptoms via reduced intra-abdominal pressure and accommodation), smoking cessation, stress management, and review of medications that may worsen symptoms (NSAIDs, bisphosphonates, iron, potassium chloride, calcium channel blockers, anticholinergics). Evidence for specific dietary interventions (low FODMAP, gluten-free) in FD is limited but may help selected patients with overlap IBS or celiac concerns.

Proton Pump Inhibitors

PPIs are first-line pharmacologic therapy for functional dyspepsia, particularly EPS subtype. Standard dose (omeprazole 20 mg PO daily, esomeprazole 20 mg PO daily, pantoprazole 40 mg PO daily, lansoprazole 30 mg PO daily, rabeprazole 20 mg PO daily) for 4-8 weeks provides symptomatic benefit with NNT of approximately 8-10. EPS responds preferentially; PDS shows less reliable response. Take 30-60 minutes before breakfast for optimal effect. If response is achieved, taper to lowest effective dose or step down to H2 receptor antagonist (famotidine 20-40 mg PO daily). Long-term continuous PPI requires periodic reassessment given concerns about osteoporosis risk, B12 deficiency, increased C. difficile, and possible CKD progression.

Prokinetics for PDS

DrugDoseCautions
Metoclopramide5-10 mg PO TID 30 min before meals + bedtimeFDA BLACK BOX: tardive dyskinesia; limit to 12 weeks; avoid Parkinson disease
Itopride (where available)50 mg PO TID before mealsD2 antagonist + AChE inhibitor; better tolerated than metoclopramide; not FDA-approved in US
Domperidone (limited availability)10 mg PO TID before mealsQT prolongation risk; obtain ECG; avoid in known QT prolongation, electrolyte disturbance, or interacting medications; not FDA-approved (FDA expanded access)
Acotiamide (Japan)100 mg PO TID before mealsAChE inhibitor + M1/M2 antagonist; approved for PDS in Japan; favorable tolerability
STW 5 (Iberogast, herbal)20 drops PO TID before mealsMulti-herb preparation; supportive evidence; favorable safety; available OTC in many countries
ErythromycinNOT recommendedTachyphylaxis; QT prolongation; antibiotic stewardship concerns

Treatment Algorithm by Subtype

SubtypeFirst-lineSecond-lineRefractory
EPS (epigastric pain)PPI 4-8 weeks; H. pylori test-and-treat if positiveAdd or switch to TCA (amitriptyline 10-25 mg qHS)Combine PPI + TCA + behavioral therapy; consider clinical trial
PDS (postprandial)Prokinetic (metoclopramide, itopride, domperidone) + dietary modificationAdd buspirone (10 mg TID); H. pylori test-and-treat if positiveMirtazapine 7.5-15 mg qHS for nausea/early satiation/weight loss; behavioral therapy
Overlap PDS + EPSPPI + prokineticAdd TCA or mirtazapine; H. pylori test-and-treat if positiveCombination triple therapy + behavioral therapy
FD with significant nausea/weight lossMirtazapine 7.5-15 mg qHS first-line; prokineticNutritional consultation; gastric emptying study to exclude gastroparesisSubspecialty referral; consider gastric electrical stimulation

S5. Refractory Disease and Neuromodulators

Tricyclic Antidepressants

Tricyclic antidepressants are second-line for refractory FD, particularly EPS subtype. Amitriptyline 10-50 mg PO at bedtime or nortriptyline 10-50 mg PO at bedtime work through gut-brain axis modulation, central pain inhibition, and improvement of visceral hypersensitivity at doses lower than antidepressant doses. The FUNCTIONAL trial showed amitriptyline significantly reduced symptoms versus placebo and escitalopram in FD, with NNT approximately 6 for global improvement. Start low and titrate every 1-2 weeks based on response and tolerability. Common side effects include drowsiness (taking at bedtime mitigates), dry mouth, constipation, and orthostatic dizziness; nortriptyline has less anticholinergic burden than amitriptyline. Avoid in patients with significant cardiac conduction disease or QT prolongation.

Mirtazapine

Mirtazapine 7.5-15 mg PO at bedtime is particularly useful for FD patients with prominent early satiation, nausea, and weight loss. Mechanisms include 5-HT3 antagonism (anti-nausea), histamine H1 antagonism (appetite stimulation, sleep), and central pain modulation. Studies demonstrate improvement in dyspepsia symptoms, reduction in nausea/vomiting, and weight gain in FD with weight loss. Side effects include sedation (use bedtime dosing) and weight gain (often desired). Useful for the malnourished, weight-losing patient where appetite stimulation is therapeutic rather than adverse.

Other Neuromodulators

DrugMechanismDoseNotes
Buspirone5-HT1A agonist10 mg PO TIDImproves gastric accommodation in PDS; adjunct rather than monotherapy
SSRI (citalopram, sertraline)Selective serotonin reuptake inhibitionCitalopram 10-20 mg PO dailyLess effective for FD specifically; useful for comorbid anxiety/depression
SNRI (duloxetine, venlafaxine)Combined 5-HT and norepinephrine reuptake inhibitionDuloxetine 30-60 mg PO dailyLimited FD-specific data; consider for chronic pain overlap
PregabalinCalcium channel modulator75 mg PO BIDOff-label; emerging data for visceral hypersensitivity
Refractory Dyspepsia Workup Reassessment Before escalating to advanced neuromodulators or invasive interventions, reassess for missed diagnosis: repeat upper endoscopy with biopsy of duodenum (eosinophilic gastritis, celiac), gastric emptying scintigraphy (gastroparesis), HIDA scan if biliary suspected, MRCP for chronic pancreatitis, EUS for pancreatic mass, and reconsider mesenteric ischemia in vascular risk patients. Confirm H. pylori eradication status. Review medications—discontinue NSAIDs, bisphosphonates, iron, calcium channel blockers when possible. Assess for psychiatric comorbidity (depression, anxiety, somatization, eating disorder, history of trauma) requiring focused intervention.

S6. Behavioral Therapy and Long-Term Care

Brain-Gut Behavioral Therapies

Brain-gut behavioral therapies are effective for refractory FD with NNT of approximately 4-6 for global symptom improvement. Cognitive behavioral therapy addresses maladaptive symptom-related thoughts and behaviors (food avoidance, fear-driven dietary restriction, restroom-mapping behavior in overlap with IBS). Gut-directed hypnotherapy uses guided imagery focused on gastric function and sensation, typically delivered in 7-12 sessions. Mindfulness-based stress reduction and yoga have supportive evidence for stress-related symptom modulation. Digital and app-based programs (e.g., Mahana FD analogs, Zemedy) increase access where in-person GI psychology is unavailable.

Psychiatric Comorbidity

Anxiety, depression, somatization, history of trauma, and eating disorders are common in FD and contribute to symptom severity, healthcare utilization, and treatment refractoriness. Screening tools (PHQ-9, GAD-7, somatization) identify patients who would benefit from focused psychiatric care. Antidepressant therapy may serve dual purpose: treating both psychiatric comorbidity and dyspepsia. Refer to psychiatry or psychology when comorbidity significantly impacts function or response to standard FD therapy.

Long-Term Course and Surveillance

FD is typically a relapsing-remitting condition over years to decades, with approximately 50% of patients reporting persistent symptoms over 10 years and 30% continuing to seek care. Patients at higher risk of chronic course include those with severe baseline symptoms, female sex, anxiety/depression, history of infection-triggered onset, and overlap with IBS or other functional GI disorders. Periodic reassessment (every 6-12 months) of symptom subtype (which can shift), severity, treatment response, and quality of life impact guides therapeutic adjustments. New or worsening alarm features (weight loss, dysphagia, bleeding, mass, age >60 with symptom change) warrant repeat endoscopy.

When to Refer to GI Specialist Refractory symptoms despite first-line PPI, prokinetic, and neuromodulator trials; suspicion of underlying organic disease requiring advanced evaluation (endoscopic ultrasound, manometry, MRCP); diagnostic uncertainty between FD, gastroparesis, and chronic nausea/vomiting syndrome requiring objective gastric emptying assessment; consideration of advanced therapy (gastric electrical stimulation, pyloric interventions); severe psychological comorbidity requiring multidisciplinary care; patients requesting access to gut-directed hypnotherapy or digital CBT programs; complex H. pylori cases (multiple eradication failures, resistance pattern guidance).

Areas of Uncertainty

The role of duodenal eosinophilia and mast cell activation as therapeutic targets is evolving; emerging trials evaluate H1 and H2 antagonists, leukotriene modifiers, and mast cell stabilizers. Rifaximin’s role in FD (analogous to its IBS-D indication) is investigational with mixed results. Vonoprazan (PCAB class) has expanding data for both EPS-predominant FD and as a more potent acid suppressant alternative to PPI. Pyloric interventions (POP — peroral pyloromyotomy, G-POEM) for refractory PDS with gastroparesis-overlap features show promise but optimal patient selection remains unclear. Microbiome-targeted therapies (probiotics, FMT) lack robust FD-specific evidence.

S7. Practice Insights: Subtype-Specific Therapy Determines Whether the Patient Returns

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A normal endoscopy is handed over as reassurance and the visit ends there, when in functional dyspepsia that result is where classification should begin — this disease is mismanaged in one specific direction: every patient gets PPI as a reflex, and the postprandial distress syndrome (PDS) patients return month after month because acid was never the dominant pathophysiology. In experienced practice, the Rome IV subtype distinction — PDS versus EPS — drives every downstream decision, and the patients experienced clinicians see relapsing are those whose subtype was never formally classified. The single question to ask at every functional dyspepsia visit is: “Are the symptoms postprandial or epigastric pain at any time?”

The Subtype Distinction That Changes Therapy

Postprandial distress syndrome (PDS, 60-70%) — bothersome postprandial fullness or early satiation occurring after meals — responds to prokinetics (mosapride, acotiamide where available, metoclopramide short-term) and motility-modulating agents, not acid suppression. Epigastric pain syndrome (EPS, 20-30%) — burning epigastric pain unrelated to meals — responds to PPI as first-line. Mixed PDS+EPS (10-20%) needs both arms. In experienced hands, the most common diagnostic-therapy mismatch is the PDS patient on PPI monotherapy for 6 months without improvement — switching to a prokinetic produces meaningful response in roughly 50-60% of these patients.

H. pylori Test-and-Treat Discipline Seasoned Clinicians Maintain

The Maastricht VI consensus and ACG guidelines support test-and-treat strategy for H. pylori in all functional dyspepsia patients. In practice, every functional dyspepsia patient gets H. pylori testing — urea breath test or stool antigen, with at least 2 weeks off PPI before testing (4 weeks ideal). H. pylori eradication produces meaningful symptom resolution in roughly 10-15% of FD patients at 12 months, which is small but real, and importantly removes a confounding diagnosis. Experienced clinicians have stopped accepting “PPI as empiric trial” before H. pylori testing — false-negative testing on PPI is a common workup failure.

The Neuromodulator Decision Experienced Practitioners Make Earlier Than Many

For refractory FD (failure of PPI ± prokinetic at 8-12 weeks), the preferred neuromodulator is amitriptyline 10-25 mg at bedtime or mirtazapine 7.5-15 mg at bedtime — the latter particularly for PDS with weight loss/early satiety because mirtazapine’s appetite-stimulating effect helps. Experienced practice adds the neuromodulator at the 8-12 week mark, not at 6 months, because the slow response (4-8 weeks to effect) means delayed initiation extends the symptomatic period unnecessarily. Experienced clinicians avoid SSRIs as first-line neuromodulator for FD because the evidence base is weaker and they can worsen nausea in PDS.

Endoscopy — Where Seasoned Clinicians Lower the Threshold

Standard guidelines advise endoscopy for FD with alarm features or age over 60 (45-55 in some). In experienced practice experienced practitioners lower this threshold meaningfully: endoscopy for any patient over 50 with new-onset symptoms, anyone with weight loss greater than 5% in 6 months, any iron deficiency anemia, persistent vomiting, family history of gastric cancer under age 50, or symptoms not responding to 8-12 weeks of subtype-directed therapy. Younger patients with classic FD without alarms can be managed without endoscopy, but in regions with high gastric cancer prevalence (Korea, Japan, parts of South America) the established threshold is even lower — experienced practice orders endoscopy for almost all new presentations.

Illustrative Scenario — PDS Misdiagnosed as Acid Reflux for 18 Months

A woman in her mid-forties was referred to the treating clinicians for “refractory GERD” after 18 months on omeprazole 40 mg twice daily without improvement. Her actual symptoms on direct questioning: bothersome postprandial fullness within 30 minutes of eating, early satiety preventing completion of normal meals, no heartburn, no regurgitation. Endoscopy was normal; H. pylori urea breath test was negative (off PPI for 4 weeks); celiac serology, thyroid, and basic labs were normal. The Rome IV criteria fit postprandial distress syndrome cleanly, with no overlap into EPS. The treating clinicians discontinued the PPI, started mosapride 5 mg three times daily before meals, and counseled on small-frequent meals plus fat reduction. At 6-week follow-up she reported substantial improvement, no longer felt full after small meals, and weight had stabilized after 18 months of involuntary loss. They added mirtazapine 7.5 mg at bedtime for the residual early satiety; at 12-week follow-up symptoms were largely resolved.

Takeaway: PDS does not respond to PPI because acid is not the dominant pathophysiology. Eighteen months of PPI for a PDS patient is wasted therapy plus continued symptoms. The Rome IV criteria distinction is not academic — it directs the right first-line agent for each subtype.

the established Protocol Adjustments to Standard FD Management

  1. Rome IV subtype classification before first-line therapy: PDS gets prokinetic first, EPS gets PPI first, mixed gets both. Do not default to PPI empirically — the wrong arm at first-line predicts non-response and patient dissatisfaction.
  2. H. pylori test-and-treat in all FD patients (off PPI 2-4 wk): UBT or stool antigen, not serology. Eradication helps 10-15% at 12 mo, removes a confounding diagnosis, and prevents future complications.
  3. Neuromodulator initiation at 8-12 weeks of first-line failure, not 6 months: Amitriptyline 10-25 mg qhs or mirtazapine 7.5-15 mg qhs (preferred in PDS with weight loss). Slow response (4-8 wk) means earlier start matters.
  4. Lower endoscopy threshold in Asian populations and any new symptoms over 50: Gastric cancer prevalence justifies broader scoping. Younger patients with classic FD without alarms can be managed without endoscopy, but the regional epidemiology is the swing factor.
FD: Rome IV Subtypes & Step-Up Therapy Two-panel diagram: left panel Rome IV subtype matrix distinguishing PDS EPS and mixed subtypes with characteristic symptoms and first-line therapy; right panel step-up therapy escalation ladder from H pylori test through first-line subtype-directed therapy to neuromodulators and behavioral therapy Rome IV Subtypes & Step-Up Therapy Rome IV Subtype Classification Bothersome dyspepsia ≥3 mo (onset ≥6 mo earlier) PDS — Postprandial Distress (60-70%) Bothersome postprandial fullness OR early satiation preventing meal completion Severe enough to impact daily activities 1L: Prokinetic (mosapride, acotiamide, MCP short-term) PPI usually unhelpful EPS — Epigastric Pain (20-30%) Bothersome epigastric pain OR epigastric burning Not exclusively postprandial 1L: PPI (omeprazole 20-40 mg, esomeprazole 40 mg) Prokinetic usually unhelpful Mixed PDS+EPS (10-20%) Symptoms of both subtypes 1L: PPI + prokinetic (both arms) ⚠ Alarm features (wt loss, anemia, vomiting) → EGD Step-Up Therapy Ladder Step 1 — H. pylori test & treat UBT or stool antigen (off PPI 2-4 wk) Eradication helps ~10-15% at 12 mo Step 2 — Subtype-directed 1L (8-12 wk) PDS: mosapride 5 mg TID • EPS: omeprazole 20-40 mg Mixed: PPI + prokinetic Step 3 — Lifestyle modifications Small frequent meals, low-fat, no late eating Avoid alcohol, NSAIDs, smoking Step 4 — Neuromodulator (refractory 8-12 wk) Amitriptyline 10-25 mg qhs OR Mirtazapine 7.5-15 mg qhs (PDS w/ weight loss) Step 5 — Behavioral & advanced therapy Gut-directed CBT, hypnotherapy Refer GI psych or multidisciplinary clinic Endoscopy threshold Lower in Asia, anyone >50 new sx, refractory cases
RELATED TOOL
H. pylori Eradication Regimen Decision Support — eradication decision support: prior treatment history, penicillin allergy, clarithromycin susceptibility and drug availability.

Frequently Asked Questions

What are the Rome IV criteria for functional dyspepsia?
Rome IV criteria require one or more of the following symptoms, severe enough to interfere with usual activities, occurring at least 3 days per week for the last 3 months with onset at least 6 months prior: bothersome postprandial fullness, bothersome early satiation, bothersome epigastric pain, or bothersome epigastric burning. There must be no evidence of structural disease (including upper endoscopy when indicated) likely to explain symptoms. Two subtypes are recognized: postprandial distress syndrome (PDS) characterized by meal-induced fullness or early satiation, and epigastric pain syndrome (EPS) characterized by epigastric pain or burning unrelated to meals. Overlap occurs in 30-40%.
When is upper endoscopy indicated in patients with dyspepsia?
The American College of Gastroenterology recommends upper endoscopy in patients with dyspepsia who are 60 years or older to exclude upper GI malignancy, regardless of symptom duration. For patients younger than 60, endoscopy is indicated when alarm features are present: unintentional weight loss, dysphagia or odynophagia, persistent vomiting, GI bleeding (overt or iron deficiency anemia), palpable abdominal mass or lymphadenopathy, family history of upper GI cancer in first-degree relative, or persistent symptoms despite empiric therapy. Test-and-treat for H. pylori is appropriate first-line for younger patients without alarm features in regions of moderate-high H. pylori prevalence (>10%).
What is the H. pylori test-and-treat strategy for functional dyspepsia?
For dyspepsia patients <60 years without alarm features in regions with H. pylori prevalence >10%, test-and-treat is first-line. Use stool antigen or urea breath test (avoid serology, which doesn’t distinguish active from past infection). PPI must be held for 2 weeks and bismuth/antibiotics for 4 weeks before testing. If H. pylori positive, eradicate with bismuth quadruple therapy (PPI BID + bismuth subsalicylate 525 mg QID + metronidazole 500 mg TID + tetracycline 500 mg QID × 14 days), or vonoprazan triple therapy where available (vonoprazan 20 mg BID + amoxicillin 1000 mg BID + clarithromycin 500 mg BID × 14 days). Confirm eradication 4 weeks after treatment. Long-term symptom improvement occurs in 5-15% of dyspepsia patients (NNT ~14).
What is the role of PPIs in functional dyspepsia?
PPIs are first-line pharmacologic therapy for functional dyspepsia, particularly for epigastric pain syndrome (EPS) subtype. Standard dose (omeprazole 20 mg, esomeprazole 20 mg, pantoprazole 40 mg, or equivalent) once daily for 4-8 weeks provides symptomatic benefit with NNT of approximately 8-10. Response is best in EPS; PDS subtype responds less reliably. If response, taper to lowest effective dose or step down to H2 receptor antagonist (famotidine 20-40 mg daily). Long-term continuous PPI is appropriate for relapsing symptoms but requires periodic reassessment given concerns about long-term safety (osteoporosis, B12 deficiency, C. diff, possible CKD progression).
What prokinetics are useful for postprandial distress syndrome?
Prokinetics target the postprandial distress syndrome (PDS) subtype with meal-related fullness and early satiation. Options include metoclopramide 5-10 mg PO TID before meals (limit to 12 weeks due to tardive dyskinesia risk—FDA black box), itopride 50 mg PO TID before meals (where available; better tolerability than metoclopramide), and domperidone 10 mg PO TID before meals (not FDA-approved in US; QT prolongation risk—obtain ECG and avoid in known QT prolongation, electrolyte disturbance, or interacting medications). Acotiamide 100 mg PO TID is approved in Japan for PDS. STW 5 (Iberogast, herbal) has supportive evidence with favorable safety. Erythromycin is not recommended due to tachyphylaxis.
What is the role of neuromodulators in refractory functional dyspepsia?
Tricyclic antidepressants (amitriptyline 10-50 mg or nortriptyline 10-50 mg at bedtime) are second-line for refractory functional dyspepsia, particularly EPS subtype. They work through gut-brain axis modulation and improvement of visceral hypersensitivity at low doses (lower than antidepressant doses). NNT is approximately 6 for global symptom improvement. Mirtazapine 7.5-15 mg at bedtime is particularly useful for patients with prominent early satiation, weight loss, and nausea, exploiting its appetite-stimulating and 5-HT3 antagonist properties. SSRIs are less effective for FD specifically. Buspirone 10 mg PO TID promotes gastric accommodation in PDS. Combine with psychological therapy (CBT, gut-directed hypnotherapy) for refractory cases.
How does functional dyspepsia differ from gastroparesis and chronic nausea?
Functional dyspepsia and gastroparesis have substantial symptom overlap (postprandial fullness, nausea, early satiation) but distinct definitions. Gastroparesis requires objective documentation of delayed gastric emptying on standardized 4-hour gastric emptying scintigraphy (>10% retention at 4 hours). FD requires absence of structural disease but does not depend on emptying studies. Many patients labeled with gastroparesis actually have functional dyspepsia with mild gastric emptying abnormalities; conversely, some with severe FD have normal emptying. Chronic nausea and vomiting syndrome (Rome IV) describes nausea without prominent dyspeptic features. Treatment overlaps but gastroparesis often requires more aggressive prokinetic therapy and dietary modification (small frequent meals, low fat, low fiber).
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

Leave a Reply

Your email address will not be published. Required fields are marked *